Three new cases of bullous pemphigoid during anti‐PD‐1 antibody therapy

Three new cases of bullous pemphigoid during anti‐PD‐1 antibody therapy EditorAnti‐programmed death 1 (PD‐1) antibodies are revolutionizing the treatment of many cancers, including melanoma. Cutaneous adverse events (AE) of anti‐PD‐1 antibodies are common (20%) and mainly non‐specific. Bullous pemphigoids (BP) are very rare immune‐related AEs induced by anti‐PD‐1 antibodies, with only 12 cases previously published. We report here three new cases of BP during anti‐PD‐1 therapy with nivolumab.The first patient was a 66‐year‐old man treated for a metastatic choroidal melanoma with nivolumab (Table ). He presented with a moderate diffuse pruritic papular eruption on his back 4 months after nivolumab initiation, associated 3 months later with tense bullae on the trunk (Fig. a). A skin biopsy confirmed the diagnosis of BP with a subepidermal blister associated with an eosinophilic infiltrate and linear IgG and C3 immune deposits along the dermoepidermal junction (DEJ) (Fig. b). Serum BP 180 antibodies by enzyme‐linked immunosorbent assay (ELISA) were positive (34 U/mL), and BP 230 antibodies were not detected. As the patient was responding to nivolumab, this latter was continued and oral prednisone was initiated at a daily dose of 0.5 mg/kg. BP was controlled within 2 weeks, and prednisone doses were gradually tapered. With a 14‐month follow‐up after initiating corticosteroids, BP is still controlled, at a daily dose of prednisone of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Three new cases of bullous pemphigoid during anti‐PD‐1 antibody therapy

Loading next page...
 
/lp/wiley/three-new-cases-of-bullous-pemphigoid-during-anti-pd-1-antibody-xtB3ik5iCA
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14579
Publisher site
See Article on Publisher Site

Abstract

EditorAnti‐programmed death 1 (PD‐1) antibodies are revolutionizing the treatment of many cancers, including melanoma. Cutaneous adverse events (AE) of anti‐PD‐1 antibodies are common (20%) and mainly non‐specific. Bullous pemphigoids (BP) are very rare immune‐related AEs induced by anti‐PD‐1 antibodies, with only 12 cases previously published. We report here three new cases of BP during anti‐PD‐1 therapy with nivolumab.The first patient was a 66‐year‐old man treated for a metastatic choroidal melanoma with nivolumab (Table ). He presented with a moderate diffuse pruritic papular eruption on his back 4 months after nivolumab initiation, associated 3 months later with tense bullae on the trunk (Fig. a). A skin biopsy confirmed the diagnosis of BP with a subepidermal blister associated with an eosinophilic infiltrate and linear IgG and C3 immune deposits along the dermoepidermal junction (DEJ) (Fig. b). Serum BP 180 antibodies by enzyme‐linked immunosorbent assay (ELISA) were positive (34 U/mL), and BP 230 antibodies were not detected. As the patient was responding to nivolumab, this latter was continued and oral prednisone was initiated at a daily dose of 0.5 mg/kg. BP was controlled within 2 weeks, and prednisone doses were gradually tapered. With a 14‐month follow‐up after initiating corticosteroids, BP is still controlled, at a daily dose of prednisone of

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off